Evolution of GCA Treatments - More to Come by Meral El Ramahi ( @MeralElRamahiMD) #ACR20 Reflecting on the innovative treatment approach to Giant Cell Arteritis (GCA) https://t.co/xuQ7Litn8t https://t.co/4NtVSMOPsS

• https://bit.ly/36ohw9z

GCA Treatment Data: Dr. David Liew Abstract ( @drdavidliew) Dr. David Liew reviews abstracts #0516 and #0513 presented at the #ACR20 annual meeting. https://t.co/KmjTRmDbA1

• https://bit.ly/3liEoNG

Read our article titled: Best Imaging Techniques for non ANCA Vasculitis by Dr. Alexa Meara ( @lexmeara) as discussed at #ACR20 https://t.co/kwXUhn8QSG https://t.co/OjTtFE6jEt

• https://bit.ly/35c92Te

Dr P Seo notes based on PEXIVAS study while PLEX does not seem to help with AAV, it showed you can drop steroid dose sooner: start pred 1 mg/kg/d but drop down after 1 week to 0.5 mg/kg/d #ACRReview #ACR20 @rheumnow

And we're off! #ACR20 year in review ⭐️@philseo's #Vasculitis lecture⭐️ Take home lessons/ remaining questions from GiACTA ⬇️ #ACRambassador https://t.co/7C9QxbUeNH

📌More #Vasculitis pearls from #ACR20 Year in Review #PEXIVAS in a nutshell ⬇️ #ACRambassador https://t.co/PnoP7QIiYs

There are a number of important mimics of IgG4-RD that should be considered 🔵ANCA-associated vasculitis 🔵Multicentric Castleman’s disease 🔵Rosai-Dorfman disease 🔵Inflammatory myofibroblastic tumour 🔵Cutaneous plasmacytosis 🔵Erdheim-Chester disease 🔵Malignancy #ACR20

TAK & GCA differ in vessel involvement when it comes to the 👁👁 > TAK- large vessel lesions > GCA- small vessel vasculitis @RheumNow #ACR20 https://t.co/sa4VEvCKOt

@RheumNow #ACR20 abs1923 prosp cohort study of angiographic lesions in Takayasu’ &GCA: although infrequent new angio lesions more likely in TAK. Improvement is possible in both conditions, more likely to occur in TAK. Change in the branch arteries more dynamic than in the aorta https://t.co/2KsZ6o3vtP

Mavrilimumab (anti-GM-CSF) in GCA, phase 2 GM-CSF upstream to both Th1 & Th17 pathways; potential for dx-modifying?? PNL induction then enrol+PNL taper GCA flare (ESR/CRP+Sx/imaging): mavrilimumab RRR 62% Enormous potential, worth exploring! Cid et al #ACR20 ABSTL06 @RheumNow https://t.co/mq5sTVGbPs

Can you give TCZ for GCA with minimal steroids? Everyone hates steroids, right? GUSTO trial: IVMP 500mg x3d +TCZ sc q1w 14/18 achieved clinical remission at 24w (but mean 11w) 13/18 relapse-free 1/18 permanent visual loss Is that tradeoff worth it? #ACR20 ABST0515 @RheumNow https://t.co/H9rgSxL6VP

Following RITAZAREM, would you use rituximab maintenance for ANCA-associated vasculitis patients (cost aside)? @RheumNow